Table 1. General features in the cohort of patients with sarcoidosis (N = 200) and comparison between the non-fibrotic and fibrotic disease groups.a .
| Features | Whole sample | Group | p | |
|---|---|---|---|---|
| Non-fibrotic disease | Fibrotic disease | |||
| (N = 200) | (n = 160) | (n = 40) | ||
| Gender, female | 126 (63) | 101 (63) | 25 (62) | 1.00 |
| Age, years | 49.4 ± 12.2 | 48.3 ± 11.5 | 53.6 ± 14.1 | 0.02 |
| Granulomas on biopsy | 176 (88) | 147 (92) | 29 (72) | < 0.01 |
| Duration of symptoms to diagnosis, months | 12 [4, 25] | 10 [4, 24] | 24 [8, 68] | 0.01 |
| Follow-up, months | 80 [42, 123] | 88 [40, 132] | 77 [44, 96] | 0.22 |
| Smoking (current or former smoker) | 68 (34) | 48 (30) | 20 (50) | 0.02 |
| Dyspnea | 78 (39) | 56 (35) | 22 (55) | 0.02 |
| Cough | 111 (56) | 84 (52) | 27 (60) | 0.09 |
| Wheezing | 59 (30) | 43 (27) | 16 (40) | 0.10 |
| Weight loss | 83 (42) | 69 (43) | 14 (35) | 0.35 |
| Fever | 40 (20) | 30 (19) | 10 (25) | 0.38 |
| Relevant systemic involvementb | 76 (38) | 60 (38) | 16 (40) | 0.77 |
| Treatment for presumed tuberculosis | 44 (22) | 33 (21) | 11 (28) | 0.35 |
| Radiological staging, n | ||||
| I | 38 | |||
| II | 97 | |||
| III | 25 | |||
| IV | 40 | |||
| FVC, % predicted | 84.9 ± 18.8 | 88.5 ± 16.8 | 70.7 ± 19.9 | < 0.01 |
| Reduced FVC | 74 (37) | 47 (29) | 27 (68) | < 0.01 |
| FEV1 /FVC ratio | 0.79 ± 0.09 | 0.78 ± 0.09 | 0.78 ± 0.10 | 0.56 |
| Pharmacological treatment | 153 (76) | 113 (71) | 40 (100) | < 0.01 |
a
Values expressed as n (%), mean ± SD, or median [Q1, Q3]. bExcluding facial palsy, peripheral adenopathy, orbital and salivary glands involvement, erythema nodosum, arthritis, and calcium metabolism disorder.